Sermorelin vs ipamorelin: receptors and rat findings

GHRH and ghrelin receptors

Sermorelin follows the GHRH route. Ipamorelin is a GHRP-class secretagogue acting through the ghrelin/GHS receptor, a different receiving system associated with the hunger-linked hormone ghrelin. Both routes can stimulate the pituitary to release GH. The review of GHRH and related endocrine signaling supplies the context for the GHRH side of that comparison.

“Secretagogue” means a substance that stimulates secretion. It is a broad family description that obscures the comparison when used as though every member had the same evidence. Starting with the receptor makes the difference easier to follow.

The ipamorelin bone experiment

The bone-mineral study of ipamorelin and GHRP-6 used adult female rats. Bone mineral content increased in that animal experiment. The drug names and the species are central to what was measured.

Turning the result into a free-floating claim about stronger human bones loses the most important part of the experiment. It is an ipamorelin/GHRP-class finding in rats. The direct sermorelin studies on this site concern growth in GH-deficient children and hormone measurements in older men. Those are substantial differences in population and endpoint.

Animal work can make a human study worth pursuing. A clinical claim about either compound still needs the corresponding human experiment. Even the measurement differs: bone mineral content and height velocity do different jobs.

Combination claims

Different receptors make simultaneous stimulation an interesting research question. The temptation is to promote that mechanistic possibility directly into a claim about a mixture’s benefits.

I’m much less confident about the mixture than the tidy receptor explanation might suggest. The papers listed here supply no controlled adult trial establishing the benefits and safety of a sermorelin–ipamorelin combination. Adding a second signal also adds questions about exposure, interactions and follow-up. No combination dose or schedule follows from the animal finding.

The body’s response to a pattern of messages matters as much as the fact that either message can raise GH. The continuous-infusion study account is a useful complication to have nearby.

Compounding and sport

Sermorelin’s Category 1 position is described under FDA’s interim Section 503A compounding framework. It concerns a bulk ingredient subject to the policy’s conditions. The category supplies neither approval of a compounded medicine nor a safety verdict.

Each compound needs its own regulatory assessment. Both compounds fall under the sports prohibition on GH secretagogues. I prefer to treat the receptor comparison and the regulatory question separately, because a shared endocrine endpoint cannot answer a pharmacy or anti-doping question. The FAQ follows the sermorelin status in more detail.